Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Secondary Malignant Neoplasm

Cancer Family

Secondary Malignant Neoplasm

CI-CAN-00000346SMNExplore in graph →

4,275 active trials56 approved drugs532 evidence items

NCIt: C4968

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14671
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 251–275 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
· Am J Hum Genet · 1994 · PMID 7977367 · validated civic_curation pubmed
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.
· Clin Cancer Res · 2019 · PMID 31068372 · validated civic_curation pubmed
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
· Cancer Res · 2013 · PMID 23786770 · validated civic_curation pubmed
Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma.
· Cold Spring Harb Mol Case Stud · 2018 · PMID 29610391 · validated civic_curation pubmed
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.
· JCO Precis Oncol · 2022 · PMID 35005993 · validated civic_curation pubmed
EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
· Lung Cancer · 2022 · PMID 35245845 · validated civic_curation pubmed
A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report.
· Onco Targets Ther · 2021 · PMID 34163176 · validated

Showing 251–275 of 486 publications

← Previous
1
…
10
11
12
…
20
Next →

civic_curation

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.

· JCO Precis Oncol · 2022 · PMID 35085007 · validated civic_curation pubmed

An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.

· Eur J Endocrinol · 2022 · PMID 35118995 · validated civic_curation pubmed

Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).

· Mod Pathol · 2020 · PMID 32457407 · validated civic_curation pubmed

Morphologic and Ancillary Studies of Pediatric Acinic Cell Carcinoma: A Single Institute Experience.

· Head Neck Pathol · 2023 · PMID 36169793 · validated civic_curation pubmed

EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?

· J Thorac Oncol · 2018 · PMID 29472054 · validated civic_curation pubmed

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.

· Transl Lung Cancer Res · 2022 · PMID 35399574 · validated civic_curation pubmed

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report.

· JTO Clin Res Rep · 2024 · PMID 38525318 · validated civic_curation pubmed

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.

· Heliyon · 2023 · PMID 38074875 · validated civic_curation pubmed

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

· J Thorac Oncol · 2013 · PMID 23524406 · validated civic_curation pubmed

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

· J Thorac Oncol · 2013 · PMID 23584301 · validated civic_curation pubmed

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.

· J Thorac Oncol · 2016 · PMID 26724472 · validated civic_curation pubmed

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

· Lung Cancer · 2014 · PMID 24192513 · validated civic_curation pubmed

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

· BMC Cancer · 2012 · PMID 23181703 · validated civic_curation pubmed

A novel K-ras mutation in colorectal cancer. A case report and literature review.

· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

· Jpn J Clin Oncol · 2010 · PMID 20522446 · validated civic_curation pubmed

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

· Cancer Discov · 2015 · PMID 26370156 · validated civic_curation pubmed

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

· Clin Cancer Res · 2016 · PMID 26787751 · validated civic_curation pubmed

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

· Lung Cancer · 2015 · PMID 25982012 · validated civic_curation pubmed